-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 12 day(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet
-
Mashup Score: 5
Micro-AbstractThe complete molecular response (CMR) and overall survival (OS) in patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia treated with front-line chemotherapy plus ponatinib versus earlier generation tyrosine kinase inhibitors were compared in a meta-analysis and meta-regression. The patients treated with front-line ponatinib versus earlier generation treatments were more likely to achieve a CMR and had greater rates of 3-year OS.
Categories: General Medicine News, Hem/OncsTweet-
Ponatinib vs Earlier-Generation TKIs for 1L Tx Newly Diagnosed Philadelphia-positive ALL [2/17/18] Jabbour et al. @DrHKantarjian CLML https://t.co/BkrYGqoskp #ALLsm #leusm n=25 early gen TKI, n=1 ponatinib study -- higher CMR and OS
-
-
Mashup Score: 0
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet-
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening
-
-
Mashup Score: 0Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 1 month(s) ago
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet-
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening
-
-
Mashup Score: 0Zoledronic Acid for Prevention of Bone Loss in Patients Receiving Primary Therapy for Lymphomas: A Prospective, Randomized Controlled Phase III Trial - 1 month(s) ago
Micro-AbstractIn patients with newly diagnosed lymphoma, low bone mineral density (BMD) is common at diagnosis and worsens with therapy. Our randomized phase III trial demonstrates that 2 doses of zoledronic acid (ZA) and supplementation with calcium and vitamin D effectively prevent further bone loss.
Categories: General Medicine News, Hem/OncsTweet-
Zoledronic Acid for Prevention of Bone Loss in Lymphoma [12/29/12] @Lymphoma_Doc @mtmdphd et al. CLML https://t.co/iPOYSXEA1M #lymsm #SuppOnc #BoneHealth - Clinical Practice Points: 1) Incr risk low BMD in ND & incr risk on Tx, 2) 2 doses ZA stabilize BMD, 3) Screening
-
-
Mashup Score: 28DA-R-EPOCH may mitigate the adverse prognostic implication of the diagnosis-to-treatment interval (DTI) in large B-cell lymphomas - 2 month(s) ago
Short diagnosis-to-treatment interval (DTI) is associated with high-risk disease and poor survival in diffuse large B-cell lymphoma (DLBCL). There is a paucity of literature on DTI and survival in DLBCL treated with first-line DA-R-EPOCH. We hypothesized that rapid initiation of DA-R-EPOCH in aggressive and high-risk DLBCL mitigates the adverse prognostic implication of short DTI.
Categories: General Medicine News, Hem/OncsTweet-
A big congratulations to my mentee Dr. @JessicaAllenMD on publication of her study further characterizing the diagnosis-to-treatment interval (DTI) as a prognostic marker in DLBCL when treated with upfront DA-R-EPOCH. #lymsm https://t.co/oJEy1rL68A https://t.co/IND7nqwHAd
-
-
Mashup Score: 0Rates of Influenza and Pneumococcal Vaccination and Correlation With Survival in Multiple Myeloma Patients - 2 month(s) ago
MicroabstractWe analyzed vaccination rates and associated outcomes of patients with multiple myelom in the INSIGHT MM study. Influenza vaccination in the prior 2 years and pneumococcal vaccination in the prior 5 years impacted overall survival versus no vaccination. Additionally, deaths due to infections were lower among vaccinated versus non-vaccinated patients. Vaccination status should be recorded in prospective clinical trials as it may affect survival.
Categories: General Medicine News, Hem/OncsTweet-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ
-
-
Mashup Score: 49
There has been a rapid expansion of novel therapeutics for hematologic malignancies, including monoclonal antibodies, small molecules, and cellular therapies, which confer different treatment-related toxicities and symptomatic adverse events (AEs) than traditional cytotoxic chemotherapies. Given that patients with blood cancers are living longer with these newer treatments, with some therapies requiring indefinite or time-intensive administration, consideration of patient-reported tolerability and effects on health-related quality of life (HRQoL) are increasingly relevant.
Categories: General Medicine News, Hem/OncsTweet-
Interested in how you can incorporate patient-reported outcomes (PROs) into your hematology clinical trials to measure treatment tolerability? Check out our latest review, with PRO gurus Drs. @BiostatGirl & @GitaThanaMD. #lymsm #leusm #mmsm https://t.co/wFKUHaX44i https://t.co/HknkE8Nbvk
-
-
Mashup Score: 30
Multiple Myeloma (MM) remains a challenging hematological malignancy despite significant advancements made during the past 2 decades. Outcomes have improved by incorporating immunomodulatory drugs, proteasome inhibitors, and anti-CD38 monoclonal antibodies into treatment algorithms that include high dose chemotherapy and autologous hematopoietic stem cell transplantation. However, many patients may eventually relapse despite these innovations. Newer therapies targeting B-Cell Maturation Antigen (BCMA) offer promise for patients with relapsed or refractory disease.
Categories: General Medicine News, Hem/OncsTweet-
Check our recent review article: Cereblon E3 Ligase Modulators Mezigdomide and Iberdomide in Multiple Myeloma #mmsm @UAMSMyeloma ➡️ https://t.co/2fGJKx5oK6 https://t.co/DxWMYRK1Bq
-
-
Mashup Score: 37
Inherited bone marrow failure syndromes (IBMFS) represent a group of diseases that result in bone marrow failure often at early ages leading to peripheral cytopenias, predisposition to hematologic and solid malignancies, and other disease-specific complications.1 The diagnosis of IBMFS can often overlap with acquired aplastic anemia (AA), which is also characterized by bone marrow hypocellularity, peripheral cytopenias, and cytopenia-related complications. While AA is typically treated with urgent related-donor allogeneic SCT (alloSCT) or immunosuppressive therapy such as cyclosporine and corticosteroids, IBMFS respond poorly to standard immunosuppressive therapy and are associated with increased transplant-related toxicity with standard myeloablative conditioning.
Categories: General Medicine News, Hem/OncsTweet-
👉👉👉Our article just out in CLML led by Dr @PatriceNasnas ➡️ Detection of #PNH clones can aid in distinction of AA vs inherited BM failure syndromes #BMFSM | #leusm #endcancer @MDAndersonNews @sanamloghavi https://t.co/ph1iN5ibAh https://t.co/9RZosangbV
-
Rates of Influenza and Pneumococcal Vaccination and Correlation with Survival in Multiple Myeloma Patients [Dec 6, 2022] @mtmdphd et al. @AjaiChari CLML https://t.co/kUQeRmdKWV #NCT02761187 #mmsm #IDonc #ClinicalTrials #caxtx https://t.co/IBFVjp7ytJ